Update on PEG-interferon α-2b as adjuvant therapy in melanoma

Research output: Contribution to journalArticlepeer-review


Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon α-2b (PEG-IFN) (Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon α-2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease.

Original languageEnglish
Pages (from-to)3901-3910
Number of pages10
JournalAnticancer Research
Issue number9
Publication statusPublished - Sep 2012


  • Adjuvant therapy
  • Melanoma
  • PEG-interferon α-2b
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Update on PEG-interferon α-2b as adjuvant therapy in melanoma'. Together they form a unique fingerprint.

Cite this